Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Single-arm, and Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH018 in Combination With Toripalimab in the Treatment of Patients With Advanced Solid Tumors

X
Trial Profile

A Multi-center, Single-arm, and Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH018 in Combination With Toripalimab in the Treatment of Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GFH 018 (Primary) ; Toripalimab (Primary)
  • Indications Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Head and neck cancer; Liver cancer; Nasopharyngeal cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors GenFleet Therapeutics
  • Most Recent Events

    • 15 Mar 2024 Last checked against Clinicaltrials.gov record.
    • 22 Feb 2024 Status changed from recruiting to completed.
    • 06 Jun 2023 Preliminary results (As of 31 Dec 2022, n=32 ) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top